Key Points
- FDA Authorization Gap: A 2Firsts review of FDA records found that some ZYN products displayed at the NACS Show were not on the agency's marketing authorization list.
- ZYN Product Range: PMI showcased ZYN Ultra in 9 mg and 11 mg strengths and its flagship ZYN range in 1.5 mg, 3 mg, 6 mg and 8 mg strengths.
- IQOS U.S. Sales: A PMI booth representative told 2Firsts that IQOS is currently sold in Florida, Texas and Mississippi, while IQOS ILUMA remains under FDA review.
- U.S. Manufacturing Investment: PMI highlighted its American operations, including a new Colorado facility that began commercial production of ZYN nicotine pouches in July 2026.
2Firsts
Las Vegas, October 9, 2026
Philip Morris International (PMI) displayed its U.S. portfolio of nicotine pouches, heated tobacco products and other smokeless tobacco products at the 2026 NACS Show in Las Vegas. The exhibition featured ZYN, IQOS and several established oral tobacco brands. A PMI booth representative told 2Firsts that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
The two-story PMI U.S. booth featured ZYN and IQOS on the first floor, with the second floor dedicated to the company's U.S. investments and business development.
ZYN Product Range and Retail Displays
The booth featured dedicated displays for ZYN Ultra and the flagship ZYN range.
Exhibition materials presented ZYN Ultra in 9 mg and 11 mg nicotine strengths, alongside ZYN Flagship products in 1.5 mg, 3 mg, 6 mg and 8 mg strengths. PMI promoted ZYN Ultra as featuring a hydro-boosted pouch and a redesigned can. A separate display listed Black Cherry, Peach and Dragonberry under a "New Flavor" heading.
PMI also presented a convenience-store retail display featuring ZYN, ZYN Ultra, IQOS devices and HEETS tobacco sticks. The display included product shelving, digital promotional screens and prices shown alongside the products.
Some ZYN Products Displayed at NACS Show Are Not on FDA's Authorized List
According to the U.S. Food and Drug Administration's (FDA) published list of authorized nicotine pouch products, 31 ZYN products had received marketing granted orders (MGOs) as of October 9, 2026.
These include 20 flagship ZYN products in 3 mg and 6 mg strengths, authorized in January 2025, and 11 ZYN Ultra products authorized in August 2026, comprising ten 9 mg variants and one 11 mg variant.
A comparison of the FDA list with PMI's NACS displays shows that some products presented at the booth were not included among those authorized. These include the 1.5 mg and 8 mg strengths of the flagship ZYN range and ZYN Ultra Arctic Mint 11 mg.
PMI identifies Arctic Mint as the commercial name for ZYN Ultra Cool Mint. The FDA's August 2026 authorization includes ZYN Ultra Cool Mint 9 mg, but not its 11 mg variant. ZYN Ultra Smooth 11 mg, sold under the commercial name Signature Smooth, is the only 11 mg ZYN Ultra product on the FDA's authorized list.
PMI stated in August that applications for other 11 mg ZYN Ultra variants remained under FDA scientific review.
The three flavors displayed under the "New Flavor" heading—Black Cherry, Peach and Dragonberry—were also absent from the FDA's published ZYN authorization list.
Separately, in June 2026, the FDA authorized 20 previously marketed ZYN products to carry a specific modified-risk claim. Those modified-risk orders covered the same 20 flagship products previously granted marketing authorization, rather than additional products.
IQOS Sales in Three U.S. States
A PMI booth representative told 2Firsts that IQOS is currently sold in Florida, Texas and Mississippi.
The representative said the IQOS products currently marketed in the United States belong to an earlier generation rather than the newer IQOS ILUMA system, which remains under FDA review.
In an April 2026 announcement, PMI confirmed that the FDA was continuing to review premarket tobacco product applications (PMTAs) for IQOS ILUMA.
The FDA also renewed modified-risk authorizations in April for the IQOS 2.4 and IQOS 3.0 systems and three associated HeatSticks products, permitting specific reduced-exposure claims. These were renewals of existing modified-risk authorizations, rather than new marketing authorizations.
At the NACS booth, 2Firsts observed IQOS devices in multiple colors alongside HEETS packs labeled Blue, Green, Bronze, Red and Amber.
U.S. Investments and Other Smokeless Tobacco Brands
The booth also displayed General Snus, Timber Wolf and Longhorn products.
The second floor was dedicated to PMI's U.S. investments, while a timeline display traced developments in the company's American business, including regulatory authorizations and corporate milestones.
In July 2026, PMI U.S. announced the opening of its Aurora, Colorado, manufacturing campus, where commercial production of ZYN nicotine pouches began that month. The company said the project represented approximately $1.2 billion in planned capital expenditure between 2024 and 2028, including spending already incurred.
The Aurora facility joins PMI's existing U.S. manufacturing operations in Owensboro, Kentucky, and Wilson, North Carolina.
2Firsts will continue reporting from the NACS Show on tobacco and nicotine products, retail developments and regulatory issues in the U.S. market.
Cover image: The PMI U.S. booth at the 2026 NACS Show in Las Vegas, featuring ZYN branding. (Photo: 2Firsts)
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
